Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1 -/- mutant mouse embryos: An investigation of the feasibility of renal cyst prevention in the foetus

Nephrology

Volumn 17, Issue 8, 2012, Pages 739-747

  Stayner, Cherie ^a   Shields, Justin ^a   Slobbe, Lynn ^a   Shillingford, Jonathan M ^b   Weimbs, Thomas ^b   Eccles, Michael R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cystic kidney disease; developmental nephrology; mTOR; Pax2; sirolimus

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; NESTIN; POLYCYSTIN 1; POLYCYSTIN 2; RAPAMYCIN; TRANSCRIPTION FACTOR PAX2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; FEMALE; FETUS; GENE DELETION; GENOTYPE; HOMOZYGOSITY; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; EMBRYO, MAMMALIAN; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETIC PREDISPOSITION TO DISEASE; GESTATIONAL AGE; HOMOZYGOTE; KIDNEY; MALE; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; PAX2 TRANSCRIPTION FACTOR; PHENOTYPE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTEIN KINASE INHIBITORS; SEQUENCE DELETION; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRPP CATION CHANNELS;

EID: 84868119743     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2012.01639.x     Document Type: Article

References (30)

1. Wilson PD,. Polycystic kidney disease. N. Engl. J. Med. 2004; 350: 151-64. (Pubitemid 38056226)
2. Guay-Woodford LM,. Murine models of polycystic kidney disease: Molecular and therapeutic insights. Am. J. Physiol. Renal Physiol. 2003; 285: F1034-1049. (Pubitemid 37421039)
3. Zerres K, Mucher G, Becker J, et al,. Prenatal diagnosis of autosomal recessive polycystic kidney disease (ARPKD): Molecular genetics, clinical experience, and fetal morphology. Am. J. Med. Genet. 1998; 76: 137-44. (Pubitemid 28117131)
4. Torra Balcells R, Ars Criach E,. Molecular diagnosis of autosomal dominant polycystic kidney disease. Nefrologia 2011; 31: 35-43.
5. Michaud J, Russo P, Grignon A, et al,. Autosomal dominant polycystic kidney disease in the fetus. Am. J. Med. Genet. 1994; 51: 240-46. (Pubitemid 24184459)
6. Boletta A,. Emerging evidence of a link between the polycystins and the mTOR pathways. PathoGenetics 2009; 2: 6.
7. Shillingford JM, Murcia NS, Larson CH, et al,. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci. U.S.A. 2006; 103: 5466-71.
8. Tao Y, Kim J, Schrier RW, Edelstein CL,. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J. Am. Soc. Nephrol. 2005; 16: 46-51. (Pubitemid 43073155)
9. Shillingford JM, Piontek KB, Germino GG, Weimbs T,. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J. Am. Soc. Nephrol. 2010; 21: 489-97.
10. Serra AL, Poster D, Kistler AD, et al,. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2010; 363: 820-29.
11. Walz G, Budde K, Mannaa M, et al,. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2010; 363: 830-40.
12. Loewith R,. A brief history of TOR. Biochem. Soc. Trans. 2011; 39: 437-42.
13. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP,. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol. Dial. Transplant. 2006; 21: 598-604. (Pubitemid 43372904)
14. Zhou J, Brugarolas J, Parada LF,. Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Hum. Mol. Genet. 2009; 18: 4428-41.
15. Stayner C, Iglesias DM, Goodyer PR, et al,. Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease. Hum. Mol. Genet. 2006; 15: 3520-28. (Pubitemid 44884119)
16. Ostrom L, Tang MJ, Gruss P, Dressler GR,. Reduced Pax2 gene dosage increases apoptosis and slows the progression of renal cystic disease. Dev. Biol. 2000; 219: 250-58. (Pubitemid 30152603)
17. Liu KJ, Arron JR, Stankunas K, Crabtree GR, Longaker MT,. Chemical rescue of cleft palate and midline defects in conditional GSK-3β mice. Nature 2007; 446: 79-82. (Pubitemid 46348041)
18. Lu W, Peissel B, Babakhanlou H, et al,. Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat. Genet. 1997; 17: 179-81.
19. Winyard PJD, Risdon RA, Sams VR, Dressler GR, Woolf AS,. The PAX2 transcription factor is expressed in Cystic and hyperproliferative dysplastic epithelia in human kidney malformations. J. Clin. Invest. 1996; 98: 451-59. (Pubitemid 26255745)
20. Dressler GR, Wilkinson JE, Rothenpieler UW, Patterson LT, Williams-Simons L, Westphal H,. Deregulation of Pax-2 expression in transgenic mice generates severe kidney abnormalities. Nature 1993; 362: 65-7. (Pubitemid 23087291)
21. Boulter C, Mulroy S, Webb S, Fleming S, Brindle K, Sandford R,. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc. Natl Acad. Sci. U.S.A. 2001; 98: 12174-9. (Pubitemid 32959846)
22. Gangloff YG, Mueller M, Dann SG, et al,. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 2004; 24: 9508-16. (Pubitemid 39391687)
23. Murakami M, Ichisaka T, Maeda M, et al,. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 2004; 24: 6710-18. (Pubitemid 38944350)
24. Hentges KE, Sirry B, Gingeras AC, et al,. FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse. Proc. Natl Acad. Sci. U.S.A. 2001; 98: 13796-801. (Pubitemid 33115978)
25. Sarbassov DD, Ali SM, Sengupta S, et al,. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 2006; 22: 159-68.
26. Amer H, Cosio FG,. Significance and management of proteinuria in kidney transplant recipients. J. Am. Soc. Nephrol. 2009; 20: 2490-92.
27. Wu M, Arcaro A, Varga Z, et al,. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am. J. Physiol. Renal Physiol. 2009; 297: F1597-605.
28. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N,. Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochim. Biophys. Acta 2010; 1804: 433-9.
29. Qin S, Taglienti M, Nauli SM, et al,. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J. Clin. Invest. 2010; 120: 3617-28.
30. Shen W, Brown NS, Finn PF, Dice JF, Franch HA,. Akt and mammalian target of rapamycin regulate separate systems of proteolysis in renal tubular cells. J. Am. Soc. Nephrol. 2006; 17: 2414-23. (Pubitemid 44300957)